Narcolepsy Drugs Market by Disease (Daytime Extreme Sleepiness, Cataplexia, and Other Disease Type) and Therapeutic Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, and Other Therapeutic Type): Global Opportunity Analysis and Industry Forecast, 2021-2030

1.1.Report description

1.2.Key benefits for stakeholders

1.3.Key market segments

1.4.Research methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study

2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.2.2.Top winning strategies

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers, restraints, and opportunity

3.5.2.Drivers

3.5.2.1.Increase in global prevalence of narcolepsy

3.5.2.2.Narcolepsy awareness programs and services

3.5.2.3.Presence of reimbursement policies regarding narcolepsy

3.5.3.Restraints

3.5.3.1.Adverse effects and risks related to narcolepsy drugs

3.5.3.2.Delayed diagnosis or misdiagnosis

3.5.4.Opportunity

3.5.4.1.Untapped markets in the developing countries

3.6.Impact of COVID-19 on the NARCOLEPSY DRUG market

3.6.1.Overview

3.6.2.Impact analysis

CHAPTER 4:NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Daytime extreme sleepiness

4.2.1.Key market trends and opportunities

4.2.2.Market size and forecast, by region

4.2.3.Market analysis, by country

4.3.Cataplexia

4.3.1.Key market trends and opportunities

4.3.2.Market size and forecast, by region

4.3.3.Market analysis, by country

4.4.Other disease type

4.4.1.Key market trends and opportunities

4.4.2.Market size and forecast, by region

4.4.3.Market analysis, by country

CHAPTER 5:NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE

5.1.Overview

5.1.1.Market size and forecast

5.2.Central nervous system stimulants

5.2.1.Market size and forecast, by region

5.2.2.Market analysis, by country

5.3.Tricyclic antidepressants

5.3.1.Market size and forecast, by region

5.3.2.Market analysis, by country

5.4.Sodium oxybate

5.4.1.Market size and forecast, by region

5.4.2.Market analysis, by country

5.5.Selective serotonin reuptake inhibitor

5.5.1.Market size and forecast, by region

5.5.2.Market analysis, by country

5.6.Other therapeutic type

5.6.1.Market size and forecast, by region

5.6.2.Market analysis, by country

CHAPTER 6:NARCOLEPSY DRUGS MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key opportunities and forecast

6.2.2.Market size and forecast, disease type

6.2.3.Market size and forecast, by therapeutic type

6.2.4.Market size and forecast, by country

6.2.4.1.U.S.

6.2.4.1.1.U.S. market size and forecast, by disease type

6.2.4.1.2.U.S. market size and forecast, by therapeutic type

6.2.4.2.Canada

6.2.4.2.1.Canada market size and forecast, by disease type

6.2.4.2.2.Canada market size and forecast, by therapeutic type

6.2.4.3.Mexico

6.2.4.3.1.Mexico market size and forecast, by disease type

6.2.4.3.2.Mexico market size and forecast, by therapeutic type

6.3.Europe

6.3.1.Key opportunities and forecast

6.3.2.Market size and forecast, by disease type

6.3.3.Market size and forecast, by therapeutic type

6.3.4.Market size and forecast, by country

6.3.4.1.Germany

6.3.4.1.1.Germany market size and forecast, by disease type

6.3.4.1.2.Germany market size and forecast, by therapeutic type

6.3.4.2.France

6.3.4.2.1.France market size and forecast, by disease type

6.3.4.2.2.France market size and forecast, by therapeutic type

6.3.4.3.UK

6.3.4.3.1.UK market size and forecast, by disease type

6.3.4.3.2.UK market size and forecast, by therapeutic type

6.3.4.4.Italy

6.3.4.4.1.Italy market size and forecast, by disease type

6.3.4.4.2.Italy market size and forecast, by therapeutic type

6.3.4.5.Spain

6.3.4.5.1.Spain market size and forecast, by disease type

6.3.4.5.2.Spain market size and forecast, by therapeutic type

6.3.4.6.Rest of Europe

6.3.4.6.1.Rest of Europe market size and forecast, by disease type

6.3.4.6.2.Rest of Europe market size and forecast, by therapeutic type

6.4.Asia-Pacific

6.4.1.Key opportunities and forecast

6.4.2.Market size and forecast, by disease type

6.4.3.Market size and forecast, therapeutic type

6.4.4.Market size and forecast, by country

6.4.4.1.Japan

6.4.4.1.1.Japan market size and forecast, by disease type

6.4.4.1.2.Japan market size and forecast, by therapeutic type

6.4.4.2.China

6.4.4.2.1.China market size and forecast, by disease type

6.4.4.2.2.China market size and forecast, by therapeutic type

6.4.4.3.Australia

6.4.4.3.1.Australia market size and forecast, by disease type

6.4.4.3.2.Australia market size and forecast, by therapeutic type

6.4.4.4.India

6.4.4.4.1.India market size and forecast, by disease type

6.4.4.4.2.India market size and forecast, by therapeutic type

6.4.4.5.South Korea

6.4.4.5.1.South Korea market size and forecast, by disease type

6.4.4.5.2.South Korea market size and forecast, by therapeutic type

6.4.4.6.Rest of Asia-Pacific

6.4.4.6.1.Rest of Asia-Pacific market size and forecast, by disease type

6.4.4.6.2.Rest of Asia-Pacific market size and forecast, by therapeutic type

6.5.LAMEA

6.5.1.Key opportunities and forecast

6.5.2.Market size and forecast, by disease type

6.5.3.Market size and forecast, by therapeutic type

6.5.4.Market size and forecast, by country

6.5.4.1.Brazil

6.5.4.1.1.Brazil market size and forecast, by disease type

6.5.4.1.2.Brazil market size and forecast, by therapeutic type

6.5.4.2.Saudi Arabia

6.5.4.2.1.Saudi Arabia market size and forecast, by disease type

6.5.4.2.2.Saudi Arabia market size and forecast, by therapeutic type

6.5.4.3.South Africa

6.5.4.3.1.South Africa market size and forecast, by disease type

6.5.4.3.2.South Africa market size and forecast, by therapeutic

6.5.4.4.Rest of LAMEA

6.5.4.4.1.Rest of LAMEA market size and forecast, by disease

6.5.4.4.2.Rest of LAMEA market size and forecast, by therapeutics

CHAPTER 7:COMPANY PROFILES153

7.1.Arena Pharmaceuticals, Inc.

7.1.1.Company overview

7.1.2.Operating business segments

7.1.3.Product portfolio

7.1.4.Business performance

7.2.BIOPROJET COMPANY

7.2.1.Company overview

7.2.2.Operating business segments

7.2.3.Product portfolio

7.3.GRAYMARK HEALTHCARE, INC.

7.3.1.Company overview

7.3.2.Company snapshot

7.3.3.Operating business segments

7.3.4.Product portfolio

7.4.Hikma Pharmaceuticals Plc

7.4.1.Company overview

7.4.2.Operating business segments

7.4.3.Product portfolio

7.4.4.Business performance

7.4.5.Key strategic moves and developments

7.5.JAZZ PHARMACEUTICALS PLC

7.5.1.Company overview

7.5.2.Operating business segments

7.5.3.Product portfolio

7.5.4.Business performance

7.5.5.Key strategic moves and developments

7.6.LIGAND PHARMACEUTICALS, INC.

7.6.1.Company overview

7.6.2.Company snapshot

7.6.3.Operating business segments

7.6.4.Product portfolio

7.6.5.Business performance

7.6.6.Key strategic moves and developments

7.7.Shionogi Inc.

7.7.1.Company overview

7.7.2.Operating business segments

7.7.3.Product portfolio

7.7.4.Business performance

7.8.Takeda Pharmaceutical Company Limited

7.8.1.Company overview

7.8.2.Company snapshot

7.8.3.Operating business segments

7.8.4.Product portfolio

7.8.5.Business performance

7.9.NOVARTIS INTERNATIONAL AG

7.9.1.Company overview

7.9.2.Company snapshot

7.9.3.Operating business segments

7.9.4.Product portfolio

7.9.5.Business performance

7.10.TEVA PHARMACEUTICAL INDUSTRIES LIMITED

7.10.1.Company overvie

7.10.2.Company snapshot

7.10.3.Operating business segments

7.10.4.Product portfolio

7.10.5.Business performance

TABLE 01.GLOBAL NARCOLEPSY DRUGS MARKET REVENUE, BY DISEASE, 2020–2030 ($MILLION)

TABLE 02.NARCOLEPSY DRUGS MARKET FOR DAYTIME EXTREME SLEEPINESS, BY REGION, 2020–2030 ($MILLION)

TABLE 03.NARCOLEPSY DRUGS MARKET FOR CATAPLEXIA, BY REGION, BY REGION, 2020–2030 ($MILLION)

TABLE 04.NARCOLEPSY DRUGS MARKET FOR OTHER DISEASE TYPE, BY REGION, 2020–2030 ($MILLION)

TABLE 05.GLOBAL NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 06.NARCOLEPSY DRUGS MARKET FOR CENTRAL NERVOUS SYSTEM STIMULANTS, BY REGION, 2020–2030 ($MILLION)

TABLE 07.NARCOLEPSY DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2020–2030 ($MILLION)

TABLE 08.SODIUM OXYBATE FOR NARCOLEPSY DRUGS MARKET REVENUE, BY REGION, 2020–2030 ($MILLION)

TABLE 09.NARCOLEPSY DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY REGION, 2020–2030 ($MILLION)

TABLE 10.NARCOLEPSY DRUGS MARKET FOR OTHER THERAPEUTIC TYPE, BY REGION, 2020–2030 ($MILLION)

TABLE 11.NARCOLEPSY DRUGS MARKET, BY REGION, 2020–2030 ($MILLION)

TABLE 12.NORTH AMERICA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 13.NORTH AMERICA NARCOLEPSY DRUG MARKET, THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 14.NORTH AMERICA NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)

TABLE 15.U.S. NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 16.U.S. NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 17.CANADA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 18.CANADA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 19.MEXICO NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 20.MEXICO NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 21.EUROPE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 22.EUROPE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 23.EUROPE NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)

TABLE 24.GERMANY NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 25.GERMANY NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 26.FRANCE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 27.FRANCE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 28.UK NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 29.UK NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 30.ITALY NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 31.ITALY NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 32.SPAIN NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 33.SPAIN NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 34.REST OF EUROPE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 35.REST OF EUROPE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 36.ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 37.ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 38.ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)

TABLE 39.JAPAN NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 40.JAPAN NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 41.CHINA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 42.CHINA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 43.AUSTRALIA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 44.AUSTRALIA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 45.INDIA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 46.INDIA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 47.SOUTH KOREA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 48.SOUTH KOREA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 49.REST OF ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 50.REST OF ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 51.LAMEA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 52.LAMEA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 53.LAMEA NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)

TABLE 54.BRAZIL NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 55.BRAZIL NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION

TABLE 56.SAUDI ARABIA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)

TABLE 57.SAUDI ARABIA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)

TABLE 58.SOUTH AFRICA NARCOLEPSY DRUG MARKET, BY DISEASE, 2020–2030 ($MILLION)

TABLE 59.SOUTH AFRICA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC, 2020–2030 ($MILLION)

TABLE 60.REST OF LAMEA NARCOLEPSY DRUGS MARKET, BY DISEASE, 2020–2030 ($MILLION)

TABLE 61.REST OF LAMEA NARCOLEPSY DRUGS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)

TABLE 62.ARENA PHARMA: COMPANY SNAPSHOT

TABLE 63.ARENA PHARMA: OPERATING SEGMENTS

TABLE 64.ARENA PHARMA: PRODUCT PORTFOLIO

TABLE 65.BIOPROJET: COMPANY SNAPSHOT

TABLE 66.BIOPROJET: OPERATING SEGMENTS

TABLE 67.BIOPROJET: PRODUCT PORTFOLIO

TABLE 68.GRAYMARK HEALTHCARE: SNAPSHOT

TABLE 69.GRAYMARK HEALTHCARE: OPERATING SEGMENTS

TABLE 70.GRAYMARK HEALTHCARE: PRODUCT PORTFOLIO

TABLE 71.HIKMA: COMPANY SNAPSHOT

TABLE 72.HIKMA: OPERATING SEGMENTs

TABLE 73.HIKMA: PRODUCT PORTFOLIO

TABLE 74.JAZZ PHARMACEUTICALS: COMPANY SNAPSHOT

TABLE 75.JAZZ PHARMACEUTICALS: OPERATING SEGMENTS

TABLE 76.JAZZ PHARMACEUTICALS: PRODUCT PORTFOLIO

TABLE 77.LIGAND PHARMACEUTICALS: COMPANY SNAPSHOT

TABLE 78.LIGAND PHARMACEUTICALS: OPERATING SEGMENTS

TABLE 79.LIGAND PHARMACEUTICALS: PRODUCT PORTFOLIO

TABLE 80.SHIONOGI: COMPANY SNAPSHOT

TABLE 81.SHIONOGI: OPERATING SEGMENTS

TABLE 82.SHIONOGI: PRODUCT PORTFOLIO

TABLE 83.TAKEDA: COMPANY SNAPSHOT

TABLE 84.TAKEDA: OPERATING SEGMENTS

TABLE 85.TAKEDA: PRODUCT PORTFOLIO

TABLE 86.NOVARTIS: COMPANY SNAPSHOT

TABLE 87.NOVARTIS: OPERATING SEGMENTS

TABLE 88.NOVARTIS: PRODUCT PORTFOLIO

TABLE 89.TEVA: COMPANY SNAPSHOT

TABLE 90.TEVA: OPERATING SEGMENTS

TABLE 91.TEVA: PRODUCT PORTFOLIO